1.51
price down icon7.93%   -0.13
after-market Handel nachbörslich: 1.51
loading
Schlusskurs vom Vortag:
$1.64
Offen:
$1.59
24-Stunden-Volumen:
317.56K
Relative Volume:
2.91
Marktkapitalisierung:
$47.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-0.5432
EPS:
-2.78
Netto-Cashflow:
$-55.26M
1W Leistung:
-32.59%
1M Leistung:
-71.83%
6M Leistung:
-78.46%
1J Leistung:
-77.43%
1-Tages-Spanne:
Value
$1.40
$1.675
1-Wochen-Bereich:
Value
$1.40
$2.30
52-Wochen-Spanne:
Value
$1.40
$11.90

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name
Firmenname
Acrivon Therapeutics Inc
Name
Telefon
617-207-8979
Name
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Name
Mitarbeiter
78
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
ACRV's Discussions on Twitter

Vergleichen Sie ACRV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ACRV
Acrivon Therapeutics Inc
1.51 47.34M 0 -69.00M -55.26M -2.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-31 Eingeleitet KeyBanc Capital Markets Overweight
2024-09-16 Hochstufung Ladenburg Thalmann Neutral → Buy
2024-04-29 Herabstufung Ladenburg Thalmann Buy → Neutral
2024-03-01 Eingeleitet JMP Securities Mkt Outperform
2023-12-15 Fortgesetzt Jefferies Buy
2023-10-05 Eingeleitet Maxim Group Buy
2023-06-02 Eingeleitet Oppenheimer Outperform
2023-05-08 Eingeleitet BMO Capital Markets Outperform
2023-04-27 Eingeleitet Ladenburg Thalmann Buy
2023-04-20 Eingeleitet H.C. Wainwright Buy
2022-12-12 Eingeleitet Cowen Outperform
2022-12-12 Eingeleitet Jefferies Buy
2022-12-12 Eingeleitet Piper Sandler Overweight
Alle ansehen

Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten

pulisher
Mar 29, 2025

Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 26, 2025

Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

JMP maintains Acrivon stock with $17 target following update - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Mar 26, 2025
pulisher
Mar 25, 2025

Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Citizens JMP reiterates Acrivon stock with $17 target By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 24, 2025

Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Citizens JMP reiterates Acrivon stock with $17 target - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Acrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy Rating - TipRanks

Mar 24, 2025
pulisher
Mar 20, 2025

Acrivon Therapeutics (ACRV) to Release Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Acrivon Therapeutics to Host Corporate R&D Event to Provide - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Acrivon Unveils Next-Gen Cancer Platform: Key Updates from Leading Oncology Experts - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Acrivon Therapeutics to Host Virtual R&D Event on March 25, 2025, Featuring Updates on ACR-368 and ACR-2316 - Nasdaq

Mar 19, 2025
pulisher
Mar 17, 2025

Acrivon Therapeutics Names Adam Levy as CFO -March 17, 2025 at 05:36 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

(ACRV) Investment Report - Stock Traders Daily

Mar 17, 2025
pulisher
Mar 16, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 33.7% in February - The AM Reporter

Mar 16, 2025
pulisher
Mar 15, 2025

Acrivon Therapeutics appoints new CFO as predecessor steps down By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 15, 2025

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 33.7% - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Acrivon Therapeutics appoints new CFO as predecessor steps down - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Acrivon Therapeutics Appoints New Chief Financial Officer - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $23.67 - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On? - MSN

Mar 12, 2025

Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Acrivon Therapeutics Inc-Aktie (ACRV) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
PERCEPTIVE ADVISORS LLC
10% Owner
Apr 11 '24
Buy
8.50
2,353,000
20,000,500
5,360,858
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):